Picture the war room. A plaintiffs' firm has just won its third consecutive bellwether trial — juries awarding eight figures each time — and the defense calls to talk settlement. Across the table sits not just the trial lawyers, but the capital behind them: tens of millions of dollars advanced over six years, compounding at funder rates, all of it riding on this conversation.
That is the mass tort business. No corner of American litigation runs on bigger numbers, or thinner margins for error. A single product-liability docket can encompass 50,000 plaintiffs, a decade of litigation, and a settlement fund measured in billions. And none of it happens without the financing machine most observers never see — the capital structure that lets firms spend $10–$50 million before a single client gets paid.
How mass torts get financed
Mass torts are built on contingency economics at industrial scale. Lead counsel — the firms appointed to steering committees in federal multidistrict litigation (MDL) — front the common-benefit work: the science, the liability experts, the bellwether trial program, the document review infrastructure. In a major pharmaceutical or product MDL, common-benefit investment routinely reaches $20–$50 million before settlement talks begin in earnest.
Few firms can self-fund that. So the capital stack has layers:
- Firm capital and bank lines: Traditional plaintiffs' firms historically funded cases from firm profits and bank credit lines secured by fee receivables. Banks remain in the picture, but their appetite for single-firm concentration risk is limited.
- Dedicated mass tort funders: Specialty finance firms — names like Parabellum, Validity, and a cluster of private-credit-style entrants — extend non-recourse or hybrid facilities secured by a firm's inventory of cases or its common-benefit fee award. Pricing typically targets 2–3x MOIC (multiple on invested capital) over a 3–5 year hold, reflecting the binary risk: if the science collapses, the inventory is worthless.
- Co-counsel and referral networks: The advertising firms that originate clients rarely finance the litigation; they refer cases to trial firms for a referral fee (often 25–40% of the fee), creating a second layer of economics on top of the funding.
The MDL structure itself shapes the returns. When a global settlement is reached — say, several billion dollars across tens of thousands of claimants — the court awards common-benefit fees to lead counsel, typically 4–8% of the fund, carved out before individual firms take their contingency shares. That common-benefit award is the asset the funders underwrote.
The return profile: venture capital with court dates
Funders describe mass tort investing as venture-like, and the comparison is apt. A portfolio of mass tort positions has a power-law outcome distribution: a handful of inventories produce the returns, several return capital, and some go to zero when causation science fails or a defendant wins summary judgment across the board.
Target economics for a mass tort funder typically look like this: 2–3x gross MOIC on winning positions, with portfolio-level IRRs in the mid-20s to mid-30s after losses. Duration is the enemy — an MDL that stretches from filing to settlement over eight years instead of four can cut the IRR nearly in half even if the multiple holds. The industry's private mantra says it cleanly: in mass torts, you do not lose money on bad science; you lose it on slow dockets.
Defendants have noticed the financing. The last decade's disclosure fights — over whether plaintiffs must reveal funding arrangements — are fundamentally about settlement leverage: defendants want to know how much staying power the other side's capital gives them. Courts have mostly required disclosure to the judge, not to the adversary, but the political pressure for broader transparency keeps building, including proposed federal legislation.
Notable economics, anonymized by pattern
The pattern repeats across the landmark dockets of the last twenty years. In the large pharmaceutical and medical-device settlements — funds ranging from $2 billion to $10+ billion — lead firms that invested early and heavily in the science captured common-benefit awards in the hundreds of millions. The firms that arrived late, buying inventory at a premium once settlement looked likely, earned thinner spreads. In the docket-ending disasters, where bellwether verdicts went the defense's way, funded firms wrote off eight-figure investments and funders absorbed total losses on those positions.
The newest frontier is the "Texas Two-Step" and bankruptcy-channel settlements — defendants using divisive mergers and Chapter 11 to resolve mass liabilities (the talc and Roundup-adjacent strategies). These maneuvers compress timelines and cap funds, which changes funder math: faster resolution helps IRR, but capped funds squeeze multiples. Funders now underwrite bankruptcy risk explicitly, and some have started pricing it as a separate scenario.
What the economics mean for everyone else
For plaintiffs' firms, the lesson is that capital strategy is now as important as trial skill — the firms winning the biggest leadership appointments are the ones that can credibly fund a $30 million common-benefit program. For defendants, understanding the other side's financing is understanding their settlement walkaway price. And for the capital markets, mass torts have become a genuine alternative asset class: uncorrelated, court-driven, and — when the science holds — capable of venture-scale returns.
Mass torts run on capital as much as on causation. LawsuitCosts.com covers the financing behind the dockets — funder pricing, inventory economics, and the return math that decides which cases get fought.